Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
| 対象疾患 | Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma |
|---|---|
| 相 | 第2相 |
| スポンサー | M.D. Anderson Cancer Center |
| ステータス | 完了 |
| 参加者数 | 100 名 |
| 介入（薬剤） | Durvalumab, Tremelimumab |
| 開始日 | 2017年5月18日 |
| 完了日 | 2025年9月11日 |
| 結果公開日 | 2026年8月5日 |
概要
This phase II trial studies how well durvalumab and tremelimumab work in treating participants with ovarian, primary peritoneal, or fallopian tube cancer that has come back or does not respond to treatment. Immunotherapy with monoclonal antibodies, such as durvalumab and tremelimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether give durvalumab and tremelimumab in combination or sequential administration works better in treating participants with ovarian, primary peritoneal, or fallopian tube cancer.
Immune-related Progression-free Survival (irPFS)
| Sequential Arm - High Grade Serous | 1.84 months |
|---|---|
| Combination Arm - High Grade Serous | 1.87 months |
| Sequential Arm - Clear Cell | 1.4 months |
| Combination Arm - Clear Cell | 2.32 months |
BENITIONS で見る ClinicalTrials.gov の原文を見る
同じ疾患の他の治験
- Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulo — Beth Israel Deaconess Medical Center
- Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carbop — AstraZeneca
- Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Trea — National Cancer Institute (NCI)
- Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunother — National Cancer Institute (NCI)
- Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or — National Cancer Institute (NCI)
- Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Can — National Cancer Institute (NCI)